Product Description
Mechanisms of Action: GABA Partial Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TPA023](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Generalized anxiety disorder|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TURNS | P2 |
Completed |
Schizophrenia |
2009-09-01 |
|
NCT00129441 | P2 |
Completed |
Schizophrenia |
2008-01-01 |
|
MK0777-019 | P2 |
Completed |
Generalized anxiety disorder |
2003-02-01 |
|
MK0777-022 | P2 |
Completed |
Generalized anxiety disorder |
2003-02-01 |